Gyrolab Spin Blog

May 20, 2014 8:55:00 PM

Faster, more efficient ways to develop diabetes biomarker assays

In the race against diabetes

With the incidence of obesity and associated type II diabetes soaring, the race is on for the pharmaceutical industry to generate even better treatment for diabetes. GLP-1 (glucagon-like peptide 1) is an important biomarker for obesity and diabetes, and indeed a number of type II diabetes drugs are targeted at the GLP-1 receptor.

 

Read More

Topics: Assay Development, Diabetes biomarkers